ClinicalTrials.govpublic full text
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
proteinuric renal disease, proteinuric kidney disease, proteinuria, proteinuria in nephrotic range, vascular endothelial growth factor inhibitors, cancer, endothelin-1 antagonist, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 807390
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.